# Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

> **NCT03188991** · PHASE2 · COMPLETED · sponsor: **NanOlogy, LLC** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Mucinous-Cystic Neoplasm

## Interventions

- **DRUG:** NanoPac®

## Key facts

- **NCT ID:** NCT03188991
- **Lead sponsor:** NanOlogy, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-29
- **Primary completion:** 2020-06-29
- **Final completion:** 2020-06-29
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188991, "Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03188991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*